Immunovant

Historical price data

Immunovant is a clinical-stage biotech focused on developing and commercializing novel anti-FcRn antibodies to treat autoimmune diseases. Its lead assets, batoclimab and IMVT-1402, are designed to efficiently reduce pathogenic IgG autoantibodies via subcutaneous injection, offering potential advantages in safety, convenience, and dosing flexibility. The company's strategy leverages the Roivant ecosystem for capital efficiency and operational execution, aiming to capture significant value in the large and growing autoimmune therapeutics market.

Focused on developing fully human monoclonal antibodies that inhibit the neonatal Fc receptor (FcRn) to promote degradation of pathogenic immunoglobulin G (IgG) autoantibodies, with a focus on subcutaneous administration.

Immunovant competes in the validated but crowded anti-FcRn space against argenx's efgartigimod (IV/SC), UCB/Jazz's rozanolixizumab (SC), and Johnson & Johnson's late-stage nipocalimab. Differentiation will hinge on demonstrating superior efficacy, convenience (pure SC dosing), safety (minimal albumin impact with IMVT-1402), and tailored dosing regimens.